81505-49-9

Basic information

• Product Name: (S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate
• Synonyms: (S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate
• CAS NO: 81505-49-9
• Molecular Weight: 261.318
• Mol File: 81505-49-9.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate(81505-49-9)
• EPA Substance Registry System: (S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate(81505-49-9)

Safety Data

• Hazardous Substances Data: 81505-49-9(Hazardous Substances Data)

Usage

General Description

(S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate, also known by its chemical formula C12H23NO5, is a compound commonly used in organic synthesis and pharmaceutical research. It is a derivative of the naturally occurring amino acid valine, and is often employed as a building block for the synthesis of peptides and other biologically active molecules. The compound functions as a protecting group, specifically for the amino group of valine, and can be selectively removed under mild conditions to reveal the free amine. This makes it a valuable tool for controlling the reactivity and selectivity of chemical reactions. (S)-(-)-Methyl 2-[(tert-butoxycarbonyl)amino]-6-hydroxypentanoate is typically prepared by the condensation of (S)-valine with tert-butyl chloroformate, followed by ester hydrolysis to obtain the desired product.

Upstream product

• 110579-52-7 (E)-(S)-2-tert-Butoxycarbonylamino-6-hydroxy-hex-4-enoic acid methyl ester 
• 219617-15-9 methyl (S)-2-[di(tert-butoxycarbonyl)amino]-6-oxohexanoate 
• 219617-13-7 dimethyl (S)-2-[di(tert-butoxycarbonyl)amino]hexanedioate 
• 615258-01-0 dimethyl (S)-2-[(tert-butoxycarbonyl)amino]hexanedioate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1118-90-7 L-homoglutamic acid 
• 77611-37-1 (S)-2-((tert-butoxycarbonyl)amino)-6-hydroxyhexanoic acid 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 5462-80-6 rac-6-hydroxynorleucine 
• 2483-48-9 (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-lysine methyl ester 
• 92136-57-7 (S)-2-tert-butoxycarbonylamino-hex-5-enoic acid methyl ester 
• 93267-04-0 N-(tert-butoxycarbonyl)-L-3-iodoalanine methyl ester 
• 97347-42-7 (+)-(S)-N₂,N₆-bis[(1,1-dimethylethoxy)carbonyl]-6-oxo-lysine methyl ester 

Downstream Products

• 1079209-08-7 C₁₉H₂₉NO₅ 
• 1460302-83-3 N-[(13S,16R)-16-methyl-14-oxo-18-oxa-8-thia-15-azatricyclo[17.3.1.0²'⁷]tricosa-1⁽²³⁾,2,4,6,19,21-hexaen-13-yl]benzenesulfonamide 
• 1460303-60-9 C₂₉H₃₉N₃O₇S 
• 1460307-04-3 C₃₀H₄₁N₃O₇S 
• 1460307-03-2 C₂₂H₂₆N₂O₅S 
• 1460307-02-1 C₁₈H₂₂N₂O₃S 
• 1460307-01-0 C₂₃H₃₀N₂O₅S 
• 81505-51-3 (D,L)-N²-Boc-N⁶-acetyl-N⁶-(benzyloxy)lysine methyl ester 
• 81505-60-4 6-(Acetyl-benzyloxy-amino)-2-amino-hexanoic acid methyl ester 
• 81505-62-6 N²,N²-(anhydromethylene-1,5-citryl)bis6-acetyl-N⁶-(benzyloxy)-(L)-lysine methyl ester 
• 81505-63-7 N²,N²-(1,5-citryl)bis6-acetyl-N⁶-(benzyloxy)-(L)-lysine> 
• 167090-40-6 (S)-2-amino-6-hydroxy-hexanoic acid methyl ester 

Relevant articles and documents

Synthesis and inhibitory activity of substrate-analog fructosyl peptide oxidase inhibitors

Abstract Fructosyl peptide oxidases (FPOXs) play a crucial role in the diagnosis of diabetes. Their main function is to cleave fructosyl amino acids or fructosyl peptides into glucosone and the corresponding amino acids/dipeptides. In this study, the subs

Catalytic Asymmetric Hydrogenation of Dehydroamino Acid Esters with Biscarbamate Protection and Its Application to the Synthesis of xCT Inhibitors

Catalytic asymmetric hydrogenation of dehydroamino acid esters with biscarbamate protection was examined for the first time to prepare optically active amino acids. The new method was successfully applied to the synthesis of new cystine–glutamate exchanger inhibitors.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.